Small molecules showing significant protection of mice against botulinum neurotoxin serotype a

Yuan-Ping Pang, Jon Davis, Shaohua Wang, Jewn Giew Park, Madhusoodana P. Nambiar, James J. Schmidt, Charles B. Millard

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Botulinum neurotoxin serotype A (BoNTA) causes a life-threatening neuroparalytic disease known as botulism that could afflict large, unprotected populations if the toxin were employed in an act of bioterrorism. Current post-exposure therapy is limited to symptomatic treatment or passive immunization that is effective for treating infant botulism at a cost of US $45,300 per treatment regimen. Antibodies can neutralize the extracellular but not the intracellular BoNTA. Moreover, antibody production, storage, and administration in a mass casualty scenario pose logistical challenges. Alternatively, smallmolecule inhibitors of BoNTA endopeptidase (BoNTAe) are sought to antagonize the extracellular or intracellular toxin. While several such molecules reportedly demonstrated efficacy in protecting cells against BoNTA, there is scant information to show that small molecules can significantly protect mammals against BoNTA. Herein we report the development of effective small-molecules BoNTAe inhibitors with promising in vivo pharmacokinetics. One such molecule has an in vivo halflife of 6.5 hours and is devoid of obvious sign of toxicity. Pre-treatment with this molecule at 2 mg/kg protected 100% and 70% of treated mice against BoNTA at 5 times of its median-lethal dose during the periods of 2 and 4 half-lives of the inhibitor, respectively. In contrast, 40% and 0% of untreated mice survived during the respective periods. Similar levels of protection were also observed with two other small molecules. These results demonstrate that small molecules can significantly protect mice against BoNTA and support the pursuit of small-molecule antagonists as a cost-effective alternative or as an adjunct to passive immunity for treating botulism.

Original languageEnglish (US)
Article numbere10129
JournalPLoS One
Volume5
Issue number4
DOIs
StatePublished - 2010

Fingerprint

botulinum toxin
Neurotoxins
serotypes
Molecules
Botulism
mice
botulism
half life
toxins
proteinases
Mass Casualty Incidents
Implosive Therapy
bioterrorism
Bioterrorism
passive immunity
Costs and Cost Analysis
Endopeptidases
Passive Immunization
Immunization
lethal dose

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Pang, Y-P., Davis, J., Wang, S., Park, J. G., Nambiar, M. P., Schmidt, J. J., & Millard, C. B. (2010). Small molecules showing significant protection of mice against botulinum neurotoxin serotype a. PLoS One, 5(4), [e10129]. https://doi.org/10.1371/journal.pone.0010129

Small molecules showing significant protection of mice against botulinum neurotoxin serotype a. / Pang, Yuan-Ping; Davis, Jon; Wang, Shaohua; Park, Jewn Giew; Nambiar, Madhusoodana P.; Schmidt, James J.; Millard, Charles B.

In: PLoS One, Vol. 5, No. 4, e10129, 2010.

Research output: Contribution to journalArticle

Pang, Y-P, Davis, J, Wang, S, Park, JG, Nambiar, MP, Schmidt, JJ & Millard, CB 2010, 'Small molecules showing significant protection of mice against botulinum neurotoxin serotype a', PLoS One, vol. 5, no. 4, e10129. https://doi.org/10.1371/journal.pone.0010129
Pang, Yuan-Ping ; Davis, Jon ; Wang, Shaohua ; Park, Jewn Giew ; Nambiar, Madhusoodana P. ; Schmidt, James J. ; Millard, Charles B. / Small molecules showing significant protection of mice against botulinum neurotoxin serotype a. In: PLoS One. 2010 ; Vol. 5, No. 4.
@article{af37a815b4f2494788cd727bb4941145,
title = "Small molecules showing significant protection of mice against botulinum neurotoxin serotype a",
abstract = "Botulinum neurotoxin serotype A (BoNTA) causes a life-threatening neuroparalytic disease known as botulism that could afflict large, unprotected populations if the toxin were employed in an act of bioterrorism. Current post-exposure therapy is limited to symptomatic treatment or passive immunization that is effective for treating infant botulism at a cost of US $45,300 per treatment regimen. Antibodies can neutralize the extracellular but not the intracellular BoNTA. Moreover, antibody production, storage, and administration in a mass casualty scenario pose logistical challenges. Alternatively, smallmolecule inhibitors of BoNTA endopeptidase (BoNTAe) are sought to antagonize the extracellular or intracellular toxin. While several such molecules reportedly demonstrated efficacy in protecting cells against BoNTA, there is scant information to show that small molecules can significantly protect mammals against BoNTA. Herein we report the development of effective small-molecules BoNTAe inhibitors with promising in vivo pharmacokinetics. One such molecule has an in vivo halflife of 6.5 hours and is devoid of obvious sign of toxicity. Pre-treatment with this molecule at 2 mg/kg protected 100{\%} and 70{\%} of treated mice against BoNTA at 5 times of its median-lethal dose during the periods of 2 and 4 half-lives of the inhibitor, respectively. In contrast, 40{\%} and 0{\%} of untreated mice survived during the respective periods. Similar levels of protection were also observed with two other small molecules. These results demonstrate that small molecules can significantly protect mice against BoNTA and support the pursuit of small-molecule antagonists as a cost-effective alternative or as an adjunct to passive immunity for treating botulism.",
author = "Yuan-Ping Pang and Jon Davis and Shaohua Wang and Park, {Jewn Giew} and Nambiar, {Madhusoodana P.} and Schmidt, {James J.} and Millard, {Charles B.}",
year = "2010",
doi = "10.1371/journal.pone.0010129",
language = "English (US)",
volume = "5",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Small molecules showing significant protection of mice against botulinum neurotoxin serotype a

AU - Pang, Yuan-Ping

AU - Davis, Jon

AU - Wang, Shaohua

AU - Park, Jewn Giew

AU - Nambiar, Madhusoodana P.

AU - Schmidt, James J.

AU - Millard, Charles B.

PY - 2010

Y1 - 2010

N2 - Botulinum neurotoxin serotype A (BoNTA) causes a life-threatening neuroparalytic disease known as botulism that could afflict large, unprotected populations if the toxin were employed in an act of bioterrorism. Current post-exposure therapy is limited to symptomatic treatment or passive immunization that is effective for treating infant botulism at a cost of US $45,300 per treatment regimen. Antibodies can neutralize the extracellular but not the intracellular BoNTA. Moreover, antibody production, storage, and administration in a mass casualty scenario pose logistical challenges. Alternatively, smallmolecule inhibitors of BoNTA endopeptidase (BoNTAe) are sought to antagonize the extracellular or intracellular toxin. While several such molecules reportedly demonstrated efficacy in protecting cells against BoNTA, there is scant information to show that small molecules can significantly protect mammals against BoNTA. Herein we report the development of effective small-molecules BoNTAe inhibitors with promising in vivo pharmacokinetics. One such molecule has an in vivo halflife of 6.5 hours and is devoid of obvious sign of toxicity. Pre-treatment with this molecule at 2 mg/kg protected 100% and 70% of treated mice against BoNTA at 5 times of its median-lethal dose during the periods of 2 and 4 half-lives of the inhibitor, respectively. In contrast, 40% and 0% of untreated mice survived during the respective periods. Similar levels of protection were also observed with two other small molecules. These results demonstrate that small molecules can significantly protect mice against BoNTA and support the pursuit of small-molecule antagonists as a cost-effective alternative or as an adjunct to passive immunity for treating botulism.

AB - Botulinum neurotoxin serotype A (BoNTA) causes a life-threatening neuroparalytic disease known as botulism that could afflict large, unprotected populations if the toxin were employed in an act of bioterrorism. Current post-exposure therapy is limited to symptomatic treatment or passive immunization that is effective for treating infant botulism at a cost of US $45,300 per treatment regimen. Antibodies can neutralize the extracellular but not the intracellular BoNTA. Moreover, antibody production, storage, and administration in a mass casualty scenario pose logistical challenges. Alternatively, smallmolecule inhibitors of BoNTA endopeptidase (BoNTAe) are sought to antagonize the extracellular or intracellular toxin. While several such molecules reportedly demonstrated efficacy in protecting cells against BoNTA, there is scant information to show that small molecules can significantly protect mammals against BoNTA. Herein we report the development of effective small-molecules BoNTAe inhibitors with promising in vivo pharmacokinetics. One such molecule has an in vivo halflife of 6.5 hours and is devoid of obvious sign of toxicity. Pre-treatment with this molecule at 2 mg/kg protected 100% and 70% of treated mice against BoNTA at 5 times of its median-lethal dose during the periods of 2 and 4 half-lives of the inhibitor, respectively. In contrast, 40% and 0% of untreated mice survived during the respective periods. Similar levels of protection were also observed with two other small molecules. These results demonstrate that small molecules can significantly protect mice against BoNTA and support the pursuit of small-molecule antagonists as a cost-effective alternative or as an adjunct to passive immunity for treating botulism.

UR - http://www.scopus.com/inward/record.url?scp=77956316779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956316779&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0010129

DO - 10.1371/journal.pone.0010129

M3 - Article

C2 - 20405003

AN - SCOPUS:77956316779

VL - 5

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e10129

ER -